Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update

Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update

Doxorubicin is an anthracycline chemotherapeutic that is widely used for treating various malignancies, including breast cancer, lymphomas, and sarcomas. Despite its efficacy, its clinical utility is limited by a well-documented risk of cardiotoxicity, which may manifest acutely or chronically. Doxo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vasvi Bhutani, Fahimeh Varzideh, Scott Wilson, Urna Kansakar, Stanislovas S. Jankauskas, Gaetano Santulli
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Journal of Cardiovascular Development and Disease
Subjects:	anthracyclines cardiomyopathy cell death DNA damage doxorubicin heart failure
Online Access:	https://www.mdpi.com/2308-3425/12/6/207
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correction: Bhutani et al. Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update. <i>J. Cardiovasc. Dev. Dis.</i> 2025, <i>12</i>, 207
by: Vasvi Bhutani, et al.
Published: (2025-06-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)

The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
by: D. A. Andreev, et al.
Published: (2024-03-01)

Cardioprotective Strategies for Doxorubicin-induced Cardiotoxicity: Present and Future
by: A. M. Chaulin, et al.
Published: (2022-03-01)

Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
by: Szponar Jaroslaw, et al.
Published: (2024-12-01)

Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
by: E. V. Artamonova
Published: (2016-09-01)

Mechanistic role of mesencephalic astrocyte-derived neurotrophic factor in myocardial ischemia/reperfusion injury
by: Fahimeh Varzideh, et al.
Published: (2024-10-01)

Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy
by: A.-S. O. Bady, et al.
Published: (2020-05-01)

Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity
by: I. T. Murkamilov, et al.
Published: (2021-03-01)

Ring Finger Protein 2 Promotes Oxidative Stress and Mitochondrial Dysfunction in Doxorubicin‐Induced Cardiotoxicity Via the Mercaptopyruvate Sulfurtransferase/Hydrogen Sulfide Pathway
by: Yi Zhong, et al.
Published: (2025-08-01)

DIAGNOSIS AND PREVENTION OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER FROM THE STANDPOINT OF AN ONCOLOGIST AND A CARDIOLOGIST
by: T. Yu. Semiglazova, et al.
Published: (2017-09-01)

Pathophysiology of Doxorubicin-Mediated Cardiotoxicity
by: Roberto Arrigoni, et al.
Published: (2025-04-01)

Extracellular RNA and Endothelial TLR3 Link Inflammation and Venous Thromboembolism
by: Luigi Savino, et al.
Published: (2024-08-01)

Functional role of circular RNA XYLT1 in vascular remodeling and oxidative stress in aging
by: Fahimeh Varzideh, et al.
Published: (2025-05-01)

Effect of pimobendan on cytokine levels in doxorubicin-induced cardiotoxicity
by: Burak Dik, et al.

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

Investigate if Metoprolol and Troxerutin Could Prevent Cardiotoxicity Mitigated by Doxorubicin
by: Fouad Zeidan Hamzah, et al.
Published: (2025-07-01)

Anthracycline-induced cardiac toxicity: A clinical review
by: Adil Abdelhameed Abbas, et al.
Published: (2019-01-01)

Enhancement of doxorubicin efficacy by diosmetin through DNA damage accumulation and P-glycoprotein inhibition in breast cancer cells
by: Monika Michalczyk, et al.
Published: (2025-08-01)

Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity
by: Rongrong Bai, et al.
Published: (2025-06-01)

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

Doxorubicin induced reversible cardiomyopathy: A Case report
by: K Tamakuwala, et al.
Published: (2015-07-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

Cardio- and nephroprotective effects of fractions isolated from Lycium barbarum (goji berry) in models of cardio- and nephrotoxicity in rats
by: Nadezhda Hvarchanova, et al.
Published: (2023-03-01)

Mechanistic Insights into Flavonoid Subclasses as Cardioprotective Agents Against Doxorubicin-Induced Cardiotoxicity: A Comprehensive Review
by: Shang W, et al.
Published: (2025-07-01)

Assessment of circulating biomarkers in a rat model of doxorubicin-induced cardiotoxicity
by: Emilia ANCA, et al.
Published: (2024-12-01)

Metabolomic profiling and biomarker identification for early detection and therapeutic targeting of doxorubicin-induced cardiotoxicity
by: Jingjing Ding, et al.
Published: (2025-04-01)

The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism
by: Shuai Shi, et al.
Published: (2025-07-01)

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients
by: Luigi Spadafora, et al.
Published: (2025-06-01)

Allelic variant 6A (rs35068180) of the MMP-3 promoter region as a predictor of cardiotoxicity after the end of adjuvant chemotherapy with doxorubicin in patients with breast cancer
by: I. A. Karput, et al.
Published: (2024-02-01)

Risk factors of doxorubicin-induced cardiomyopathy in non-muscle- invasive bladder cancer
by: I Made Nugraha Gunamanta Sabudi, et al.
Published: (2024-11-01)

Mitochondrial Amount Determines Doxorubicin‐Induced Cardiotoxicity in Cardiomyocytes
by: Weiyao Xiong, et al.
Published: (2025-03-01)

Research on Doxorubicin-Induced Cardiotoxicity Mechanism and Its Forensic Application
by: ZHANG Shuai, et al.
Published: (2025-04-01)

5-Oxoproline prevents doxorubicin-induced cardiotoxicity and tumor growth
by: Xinning Guo, et al.
Published: (2025-09-01)

Creation of anthracycline prodrug
by: A. N. Tevyashova
Published: (2014-12-01)

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications
by: Fulvio Borella, et al.
Published: (2024-12-01)

Curcumin exerts protective effects against doxorubicin-induced cardiotoxicity
by: O. О. Klymenko, et al.
Published: (2025-02-01)

Racial and Ethnic Disparities in Cardiotoxicity in Patients With Cancer Treated With Anthracyclines
by: Lili Zhang, et al.
Published: (2025-04-01)

Non-Coding RNAs in the Regulation of Doxorubicin-Induced Cardiotoxicity
by: Mengyao Sun, et al.
Published: (2025-05-01)

Combined effects of metformin and coenzyme Q10 on doxorubicin-induced cardiotoxicity in male wistar rats
by: Faraz Mahdizadeh, et al.
Published: (2025-07-01)